Journal article icon

Journal article

A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting

Abstract:

Background: Total arterial grafting is increasingly preferred in coronary artery bypass grafting, but it increases blood loss. Aprotinin (Trasylol; Bayer Corp, Leverkusen, Germany) reduces blood loss in cardiac surgery but has not been subjected to a randomized trial in total arterial grafting. Methods: A single-center, randomized, double blind, placebo-controlled trial of aprotinin administration in total arterial grafting was performed. The primary outcome variable was postoperative blood l...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Surgical Sciences
Role:
Author
Journal:
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Volume:
126
Issue:
4
Pages:
1087-1094
Publication date:
2003-10-05
DOI:
ISSN:
0022-5223
URN:
uuid:156f114d-fc23-48b7-8128-a3802e0099e1
Source identifiers:
143387
Local pid:
pubs:143387
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP